Clinical results reveal new opportunities and setbacks in rare disease and cancer care, shaping treatment strategies and future regulatory decisions.
|Articles|June 1, 2017
- BioPharm International-06-01-2017
- Volume 30
- Issue 6
BioPharm International, June 2017 Issue (PDF)
Click the title above to open the BioPharm International June 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
Troubleshooting Lab Operations: Be Proactive, Not Reactiveover 9 years ago
Unifying Continuous Biomanufacturing Operationsover 9 years ago
N-Glycan Analysis of Biotherapeutic Proteinsover 9 years ago
Ensure Quality in a Contract Test Laboratoryover 9 years ago
Storing and Shipping Frozen APIs in Single-Use Containersover 9 years ago
Drug Spending Not Driving Rising Healthcare Costsover 9 years ago
Managing Residual Impurities During Downstream Processingover 9 years ago
A Novel Metric for Continuous Improvement During Stage ThreeAdvertisement
Related to this article
Phase 3 interim data for RYZ101, the lead asset from Bristol Myers Squibb’s $4.1 billion RayzeBio deal, meet the primary endpoint.
Efzimfotase alfa missed significance on the six-minute walk test in adolescents and adults, while the FDA review of the therapy proceeds toward 2027.
Odyssey's 146-patient phase 2a trial will pair OD-001 with vedolizumab, targeting both innate and adaptive immune drivers of ulcerative colitis.
MT027, T-MAXIMUM's B7-H3 CAR-T therapy, earns a second FDA-cleared phase 2 trial, now testing lung and breast cancer brain metastases.
New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Advertisement
Advertisement